Concord Biotech Limited
CONCORDBIO · General/Diversified · NSE
₹1,139
Current Market Price
Fair Value (DCF)
₹605
Discount to FV
-46.9%
Updated just now
YieldIQ Score
50/100
Piotroski F-Score
6/9
Economic Moat
Wide
Confidence
61%
ROE
20.5%
Debt/Equity
0.00
WACC
10.7%
Market Cap
₹11,914 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
30.3%
Return on capital employed
EV / EBITDA
22.7×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
934.1×
EBIT covers interest
Current Ratio
6.17×
Short-term liquidity
Asset Turnover
0.53×
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.1%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,138.8
Bear case
Discount -254.5%
Base case
Discount -88.2%
Bull case
Discount -55.7%
Ratio Trends
CONCORDBIO · last 4 annual periods
ROE
20.5%
ROCE
30.3%
Operating Margin
—
Debt / Equity
0.00×
PE
—
EV / EBITDA
—
Historical Financials
CONCORDBIO · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 NSE_XBRL | 2025 yfinance | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹708 Cr | ₹831 Cr | ₹998 Cr | ₹1180 Cr | +18.5% |
| EBITDA | ₹293 Cr | ₹381 Cr | ₹469 Cr | ₹549 Cr | +23.3% |
| EBIT | — | — | ₹412 Cr | — | +0.0% |
| PAT | ₹175 Cr | ₹240 Cr | ₹308 Cr | ₹372 Cr | +28.6% |
| EPS (diluted) | — | — | ₹29.45 | — | +0.0% |
| CFO | ₹207 Cr | ₹246 Cr | ₹265 Cr | ₹245 Cr | +5.6% |
| CapEx | ₹-156 Cr | ₹-145 Cr | ₹-85.7 Cr | ₹-111 Cr | — |
| FCF | ₹52.0 Cr | ₹101 Cr | ₹180 Cr | ₹133 Cr | +36.9% |
| Total Assets | ₹1313 Cr | ₹1514 Cr | ₹1701 Cr | ₹2034 Cr | +15.7% |
| Total Debt | ₹62.5 Cr | ₹31.5 Cr | ₹9.7 Cr | ₹3.0 Cr | -63.8% |
| Shareholders' Equity | ₹1103 Cr | ₹1290 Cr | ₹1527 Cr | ₹1813 Cr | +18.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
CONCORDBIO vs 2 closest peers by market-cap band
Click a ticker to view its fair-value analysis.
Dividend History
2 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹19.45/sh
Last payout
2025-09-03
₹10.70
Peak payout
₹10.70
Trailing yield
0.94%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Concord Biotech Limited (CONCORDBIO.NS) trades at 1138.80 vs a model fair value of 605.03, a gap of -46.9%. Piotroski F-score: 6/9. Moat ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of CONCORDBIO →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for CONCORDBIO →
Compare
Head-to-head with peers
Compare CONCORDBIO side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse CONCORDBIONow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.